Replies to post #165637 on Biotech Values

[biocqr]

IDRA: How significant is it that the MOA of IMO-3100 involves the IL-17 pathway?

DNA microarray (available on biopsies from a subset of pts) showed IMO-3100 treated pts had significant improvement in the expression profiles of MAD-3 psoriasis genes and IL-17 related genes.

Biopsy samples from six pts treated with the .16 mg/kg and six with the placebo were analyzed by DNA microarray fro expression of the MAD-3 gene set (related to the pathogenesis of proiasis and genes unique to the IL-17 pathway, a critical mechanism of immunopathology.

The pts treated with IMO-3100 showed significant improvement compared to placebo in expression profile of both disease associated MAD-3 genes and the IL-17 pathway genes (each p<10-6)

https://docs.google.com/viewer?url=http%3A%2F%2Fwww.iderapharma.com%2Fdevelopment%2FIID_Poster_2013.pdf

Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0044274

Novartis grabs lead IL-17 program as Ensemble adds another marquee deal

Last month Novartis boasted that it's anti-IL-17 treatment, secukinumab, beat out Enbrel in a head-to-head psoriasis study. This new deal with Ensemble offers a complementary oral companion to an injectable Novartis recently tapped as one of 14 leading drug hopefuls in the late-stage pipeline. In addition to psoriasis, Novartis plans to release more late-stage results on secukinumab for arthritic conditions next year. And the pharma giant told investors two years ago that secukinumab was a blockbuster contender, with its first regulatory filing slated for later this year.

http://www.fiercebiotech.com/story/novartis-grabs-lead-il-17-program-ensemble-adds-another-marquee-deal/2013-08-06#ixzz2d57BVJai

[bronaess]

A PUBLIC forum in a responsible society entails an innate commitment to self-education, even if a layperson relevant to a professional discipline. ‘mcbio’ as a monicker implies a learned respondent, one disseminating information upon whence a responsible reader can base important decisions for their welfare.  This entire post is a melange of selective excerpt plus questions positioned as raison d'être.  Proclaiming, “there have been a lot of failures with TLRs over the years." is supreme anti-science and a disservice to ALL members. TLRs which / what / when??   The presumptuous 'factoid' re DVAX is egregiously misleading and lacking relevant substantiation.  

This response links to the post from ‘CynicalTrader', one irrespective of training or knowledge base, contributing a RESPONSIBLE thread of accessible facts and links in their post.  To state 'I don't know' or ask 'Why?' is a responsible and intelligent process.   Talking-head narrative on an investment site intended to provide answers rather than fuel speculation is a violation of public trust.  To evaluate the potential re an investment in Idera Pharmaceuticals relevant to IMO-3100, one starts with:  'What is the pathophysiology of Psoriasis?'   If not understood, utilize invaluable web resources starting with Wikipedia , NIH, etc.  Then,  an analysis asks:   'Is a 29 day trial of IMO-3100 consistent with known disease?'   ('mcbio' waxes onward re his analysis re responses in the drug trial to infer answers after citing 29days sans asking this initial question.)  As cited by 'CynicalTrader', Idera has rapidly moved forward to a 12week trial with IMO-8400.  Why is 'mcbio' offering blog-bites re IMO-3100 from the 29day trial with zero adherence to Sir Francis' Scientific Method?  

Each to their own, but if my Retirement funds and family welfare, would START at the beginning.  What is an "agonist" per this post of  'mcbio' and the implications for such as a pharmaceutical for a patient with psoriasis?   Then:  What background information is provided on the Idera Pharmaceutical website?   Does Idera describe either IMO-3100 or IMO-8400 as an "agonist"?  Whether selecting a candidate at the ballot box or a critical investment vehicle, knowledge is intrinsically discrete from the opine of  'blog'.  To responsibly state:  'I don't know, but want to LEARN' should insure invaluable service from this site.  Blog should never be admixed with a chest pounding bouillabaisse of snippets, questions and incorrect vocabulary for the layperson to decipher. 'mcbio' is encouraged to build upon KNOWLEDGE starting with the excellent post from 'CynicalTrader' for the common good.